In the quest to outshine the broader market, stock pickers diligently seek out stocks with the potential for superior performance. Making the right choices can significantly elevate your wealth.
In the latest session, Ironwood Pharmaceuticals Inc (NASDAQ: IRWD) closed at $3.86 up 23.32% from its previous closing price of $3.13. In other words, the price has increased by $23.32 from its previous closing price. On the day, 5.8 million shares were traded. IRWD stock price reached its highest trading level at $3.925 during the session, while it also had its lowest trading level at $3.25.
Ratios:
For a deeper understanding of Ironwood Pharmaceuticals Inc’s stock, let’s take a closer look at its various ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 4.47 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 9.28. For the most recent quarter (mrq), Quick Ratio is recorded 1.13 and its Current Ratio is at 1.13.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Nov 17 ’25 when Gaskins Tammi L sold 6,016 shares for $3.32 per share. The transaction valued at 19,973 led to the insider holds 235,264 shares of the business.
Gaskins Tammi L bought 6,324 shares of IRWD for $21,312 on Nov 17 ’25. On Aug 11 ’25, another insider, Gaskins Tammi L, who serves as the Chief Commercial Officer of the company, sold 1,316 shares for $0.84 each. As a result, the insider received 1,105 and left with 241,280 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, IRWD now has a Market Capitalization of 627939520 and an Enterprise Value of 1085772544. As of this moment, Ironwood’s Price-to-Earnings (P/E) ratio for their current fiscal year is 25.00, and their Forward P/E ratio for the next fiscal year is 8.63. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.85. Its current Enterprise Value per Revenue stands at 3.203 whereas that against EBITDA is 7.453.
Stock Price History:
The Beta on a monthly basis for IRWD is 0.13, which has changed by 0.09659088 over the last 52 weeks, in comparison to a change of 0.12934029 over the same period for the S&P500. Over the past 52 weeks, IRWD has reached a high of $5.13, while it has fallen to a 52-week low of $0.53. The 50-Day Moving Average of the stock is 94.00%, while the 200-Day Moving Average is calculated to be 202.51%.
Shares Statistics:
For the past three months, IRWD has traded an average of 1.94M shares per day and 3010540 over the past ten days. A total of 162.68M shares are outstanding, with a floating share count of 156.69M. Insiders hold about 3.68% of the company’s shares, while institutions hold 91.65% stake in the company. Shares short for IRWD as of 1763078400 were 7154955 with a Short Ratio of 3.69, compared to 1760486400 on 4702015. Therefore, it implies a Short% of Shares Outstanding of 7154955 and a Short% of Float of 6.6599995.
Earnings Estimates
. The current rating of Ironwood Pharmaceuticals Inc (IRWD) is the result of assessments by 2.0 analysts actively engaged in evaluating its market dynamics.The consensus estimate for the next quarter is $0.02, with high estimates of $0.08 and low estimates of -$0.04.
Analysts are recommending an EPS of between $0.32 and $0.27 for the fiscal current year, implying an average EPS of $0.29. EPS for the following year is $0.46, with 3.0 analysts recommending between $0.5 and $0.41.
Revenue Estimates
A total of 3 analysts believe the company’s revenue will be $58.43M this quarter.It ranges from a high estimate of $60.6M to a low estimate of $57M. As of. The current estimate, Ironwood Pharmaceuticals Inc’s year-ago sales were $90.55MFor the next quarter, 3 analysts are estimating revenue of $38.2M. There is a high estimate of $38.2M for the next quarter, whereas the lowest estimate is $38.2M.
A total of 3 analysts have provided revenue estimates for IRWD’s current fiscal year. The highest revenue estimate was $309.1M, while the lowest revenue estimate was $305.6M, resulting in an average revenue estimate of $306.97M. In the same quarter a year ago, actual revenue was $351.41MBased on 3 analysts’ estimates, the company’s revenue will be $319.47M in the next fiscal year. The high estimate is $334.2M and the low estimate is $310.2M.
